<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id><journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id><journal-id journal-id-type="publisher-id">Drug Design, Development and Therapy</journal-id><journal-title-group><journal-title>Drug Design, Development and Therapy</journal-title></journal-title-group><issn pub-type="epub">1177-8881</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4521678</article-id><article-id pub-id-type="doi">10.2147/DDDT.S88023</article-id><article-id pub-id-type="publisher-id">dddt-9-3767</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="31430" pm="."><plain>Albumin-bound paclitaxel in solid tumors: clinical development and future directions </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kundranda</surname><given-names>Madappa N</given-names></name><xref ref-type="aff" rid="af1-dddt-9-3767">1</xref><xref ref-type="corresp" rid="c1-dddt-9-3767"/></contrib><contrib contrib-type="author"><name><surname>Niu</surname><given-names>Jiaxin</given-names></name><xref ref-type="aff" rid="af2-dddt-9-3767">2</xref></contrib></contrib-group><aff id="af1-dddt-9-3767"><label>1</label>Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA</aff><aff id="af2-dddt-9-3767"><label>2</label>Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, AZ, USA</aff><author-notes><corresp id="c1-dddt-9-3767">Correspondence: Madappa N Kundranda, Banner MD Anderson Cancer Center, Medical Oncology, 2940 Suite 450, E Banner Gateway Dr, Gilbert, AZ 85234, USA, Tel +1 480 256 3623, Fax +1 480 256 4003, Email <email>madappa.kundranda@bannerhealth.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2015</year></pub-date><volume>9</volume><fpage>3767</fpage><lpage>3777</lpage><permissions><copyright-statement>© 2015 Kundranda and Niu. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2015</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="31431" pm="."><plain>Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel’s indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice. </p></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd><italic>nab</italic>-paclitaxel</kwd><kwd>breast</kwd><kwd>lung</kwd><kwd>pancreas</kwd><kwd>ovarian</kwd><kwd>melanoma</kwd></kwd-group></SecTag></article-meta></front><body><sec><title><text><SENT sid="31435" pm="."><plain>Nab-paclitaxel development </plain></SENT>
</text></title><p><text><SENT sid="31436" pm="."><plain>Paclitaxel is widely used for the treatment of solid tumors;1–3 however, the solvent used in the commercial formulation of solvent-based (sb)-paclitaxel, polyoxyethylated castor oil (Kolliphor® EL, formerly known as Cremophor EL; BASF SE, Ludwigshafen, Germany), is associated with severe, sometimes fatal hypersensitivity reactions.4–6 To reduce the risk of hypersensitivity reactions with sb-paclitaxel, patients are routinely pretreated with corticosteroids and antihistamines.1,2 Furthermore, some studies have shown that Kolliphor EL can entrap paclitaxel in solvent micelles, making the drug less available to enter tumors, thereby limiting its clinical efficacy.6–8 <p><text><SENT sid="31437" pm="."><plain>Nab-paclitaxel is a solvent-free albumin-bound form of paclitaxel.2,3,9 Compared with sb-paclitaxel, nab-paclitaxel has several advantages, including the ability to deliver significantly higher doses of paclitaxel over a shorter infusion time (30 minutes vs 3 hours for sb-paclitaxel) and the elimination of the need for pre-medications to prevent hypersensitivity reactions. Other advantages of nab-paclitaxel over sb-paclitaxel include enhanced transport of paclitaxel across endothelial cells and greater delivery of paclitaxel to tumors.9 Because nab-paclitaxel is formulated with albumin, it is postulated that the drug uses endogenous albumin transport pathways, including receptor-mediated transcytosis, to cross endothelial cell monolayers and enter tumors.9,10 In a preclinical study, fourfold more nab-paclitaxel was transported across endothelial cells than sb-paclitaxel.9 Moreover, it was found that Kolliphor EL inhibited the binding of paclitaxel to albumin and endothelial cells, potentially limiting intratumoral uptake of paclitaxel.9 Albumin, or albumin-bound molecules such as nab-paclitaxel, may also find a way into the tumor microenvironment via the enhanced permeation and retention effect, which proposes that molecules are able to escape the circulation through gaps between endothelial cells resulting from leaky vasculature around tumors.11 A comprehensive review of nab-paclitaxel’s mechanism of action and delivery system has recently been published.12 <p><text><SENT sid="31439" pm="."><plain>Recent studies on the population pharmacokinetics (PK) and pharmacodynamics (PD) of nab-paclitaxel demonstrated that pharmacologic features of nab-paclitaxel appear to be distinct from those of sb-paclitaxel.13,14 These distinct features likely contribute to the differences in clinical safety and efficacy between the two paclitaxel formulations.13 Specifically, compared with sb-paclitaxel, nab-paclitaxel was associated with faster and deeper tissue penetration and slower elimination of paclitaxel. Tissue distribution of paclitaxel was found to be dependent on the drug carrier complex.14 These results confirm preclinical findings that more paclitaxel may be able to enter the tumor when delivered as nab-paclitaxel9 – and with more rapid distribution to tissues, the duration of high systemic exposure is shorter. This may, in turn, explain the observation of the lower frequency of some severe adverse events, such as neutropenia, with nab-paclitaxel than with sb-paclitaxel, despite that nab-paclitaxel demonstrates a higher paclitaxel dose intensity (26%–49% higher) than sb-paclitaxel.15–17 Furthermore, in the population PK/PD study, a threshold plasma concentration for nab-paclitaxel was defined at 0.84 mM, such that the duration of time spent above this concentration predicted the probability of neutropenia.13 Compared with that previously reported for sb-paclitaxel (0.05 mM), the threshold plasma paclitaxel concentration was nearly 17-fold higher for nab-paclitaxel.13 Consistent with these findings, in trials to establish the maximum tolerated dose (MTD) of nab-paclitaxel, it was found that the albumin-bound formulation of paclitaxel allowed for a higher dose delivery of paclitaxel compared with sb-paclitaxel. The MTD of nab-paclitaxel was 71% to 88% higher than that reported for sb-paclitaxel for both the every-3-weeks (q3w) regimen (300 vs 175 mg/m2) and the weekly regimen (150 vs 80 mg/m2) in patients with advanced or metastatic solid tumors.18–20 Dose-limiting toxicities in these trials included neutropenia, peripheral neuropathy, stomatitis, and superficial keratopathy.18–20 With respect to peripheral neuropathy, a common taxane-associated side effect, the incidence of peripheral neuropathy with nab-paclitaxel compared to with sb-paclitaxel has varied across trials.15,16 Differences in patient populations, dosing schedules, and adverse-event management strategies may have played a role in the varying incidence rates. Nevertheless, the ability to deliver a higher dose of paclitaxel and the enhanced tissue distribution and tumor uptake of nab-paclitaxel versus sb-paclitaxel likely contribute to the more favorable efficacy and safety profile of the albumin-bound formulation of paclitaxel. </sec><sec><title><text><SENT sid="31444" pm="."><plain>Nab-paclitaxel in breast cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer </plain></SENT>
</text></title><sec><title><text><SENT sid="31445" pm="."><plain>Breast cancer </plain></SENT>
</text></title><p><text><SENT sid="31446" pm="."><plain>A Phase I dose-escalation trial of 19 patients with advanced solid tumors established the MTD of nab-paclitaxel at 300 mg/m2 given q3w.18 Dose-limiting toxicities included peripheral neuropathy, stomatitis, and superficial keratopathy, which occurred at a dose of 375 mg/m2. </plain></SENT>
<SENT sid="31447" pm="."><plain>There were no reported hypersensitivity reactions despite the absence of steroid premedication and a short infusion time (30 minutes). </plain></SENT>
<SENT sid="31448" pm="."><plain>The MTD and schedule were subsequently evaluated in a Phase II trial for the first- or ≥ second-line treatment of patients with metastatic breast cancer (MBC). </plain></SENT>
<SENT sid="31449" pm="."><plain>The trial reported an overall response rate (ORR) of 48% for the intent-to-treat population of patients, with a 64% ORR in chemotherapy-naïve patients.21 Time to tumor progression was 6.1 months and median overall survival (OS) was 14.6 months. These results supported the study of nab-paclitaxel vs sb-paclitaxel in a Phase III trial of patients with MBC.15 In this study, the dose of nab-paclitaxel was reduced to 260 mg/m2 q3w to lower the risk for severe toxicities, but the dose intensity was still 49% higher than that of sb-paclitaxel, which was dosed at 175 mg/m2 q3w.15Nab-paclitaxel demonstrated a significantly higher ORR (33% vs 19%; P=0.001; primary endpoint) and significantly longer time to tumor progression (5.3 vs 3.9 months; P=0.006) compared with sb-paclitaxel (Table 1). </plain></SENT>
<SENT sid="31451" pm="."><plain>OS was not significantly different between the two paclitaxel treatments for the overall population (14.9 vs 12.8 months; P=0.374), but patients who received nab-paclitaxel as second-line or greater did have a significantly longer OS than those who received sb-paclitaxel (13.0 vs 10.7 months; hazard ratio [HR] 0.73; P=0.024). </plain></SENT>
<SENT sid="31452" pm="."><plain>Grade 4 neutropenia was more common with sb-paclitaxel than with nab-paclitaxel (22% vs 9%), but the incidence of grade 3 sensory neuropathy was higher with nab-paclitaxel than with sb-paclitaxel (10% vs 2%) (Table 1). </plain></SENT>
<SENT sid="31453" pm="."><plain>Sensory neuropathy was managed with dose interruptions or reductions and improved to grade 2 or less in a median of 22 days. <p><text><SENT sid="31454" pm="."><plain>Based on these positive results, nab-paclitaxel received its first US Food and Drug Administration (FDA) approval in 2005 for the treatment of MBC. Nab-paclitaxel is indicated for patients with breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.3 Prior therapy should have included an anthracycline unless clinically contraindicated. </sec><sec><title><text><SENT sid="31455" pm="."><plain>NSCLC </plain></SENT>
</text></title><p><text><SENT sid="31456" pm="."><plain>A Phase II dose-finding study found that 100 mg/m2 weekly nab-paclitaxel combined with q3w carboplatin area under the concentration–time curve (AUC) 6 provided the best clinical benefit–risk ratio compared with several other doses/schedules of nab-paclitaxel plus carboplatin in patients with advanced NSCLC.22 This dose/schedule showed comparable efficacy to the other dosing cohorts and had the least severe adverse events. These results led to a larger Phase III trial of more than 1,000 patients with advanced NSCLC in which the mentioned dose/schedule of nab-paclitaxel plus carboplatin was compared with 200 mg/m2 sb-paclitaxel plus carboplatin AUC 6 q3w.16 The study met its primary endpoint with improvement in ORR for nab-paclitaxel plus carboplatin versus sb-paclitaxel plus carboplatin (33% vs 25%; P=0.005; Table 1). </plain></SENT>
<SENT sid="31458" pm="."><plain>However, there was no statistically significant difference in median progression-free survival (PFS) (6.3 vs 5.8 months) or median OS (12.1 vs 11.2 months) for nab-paclitaxel plus carboplatin versus sb-paclitaxel plus carboplatin (Table 1). </plain></SENT>
<SENT sid="31459" pm="."><plain>A subset analysis of the Phase III trial based on predefined stratification factors revealed that patients with squamous histology treated with nab-paclitaxel plus carboplatin had a significantly higher ORR compared with those who received sb-paclitaxel plus carboplatin (41% vs 24%; P&lt;0.001). </plain></SENT>
<SENT sid="31460" pm="."><plain>In addition, the median OS was significantly longer in patients ≥70 years of age who were treated with nab-paclitaxel plus carboplatin compared with sb-paclitaxel plus carboplatin (19.9 vs 10.4 months; P=0.009). </plain></SENT>
<SENT sid="31461" pm="."><plain>In the overall treated population, grade ≥3 neutropenia (47% vs 58%) and sensory neuropathy (3% vs 12%) occurred significantly less frequently with nab-paclitaxel plus carboplatin (P&lt;0.001; Table 1), while grade ≥3 thrombocytopenia (18% vs 9%) and anemia (27% vs 7%) were more common with nab-paclitaxel plus carboplatin than with sb-paclitaxel plus carboplatin (P&lt;0.001). </plain></SENT>
<SENT sid="31462" pm="."><plain>The safety profiles were similar, regardless of patient age or histology.23,24 Based on the findings of this Phase III trial, the FDA-approved nab-paclitaxel in combination with carboplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC who are not candidates for curative surgery or radiation.3 </sec><sec><title><text><SENT sid="31463" pm="."><plain>Pancreatic cancer </plain></SENT>
</text></title><p><text><SENT sid="31464" pm="."><plain>Gemcitabine monotherapy is one of the most widely used agents in the treatment of metastatic pancreatic cancer, based on a seminal study by Burris et al that demonstrated a median survival of ≈6 months.25 A decade later and after numerous failed clinical trials, erlotinib in combination with gemcitabine was FDA approved for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer,26 partly based on a statistically significant 0.3-month survival advantage for erlotinib plus gemcitabine vs gemcitabine alone.27 However, in routine clinical practice, this combination is very selectively used in a small subset of patients. Several other Phase III trials of gemcitabine doublets failed to demonstrate a significant survival advantage over gemcitabine alone.25,27–32 <p><text><SENT sid="31466" pm="."><plain>Nab-paclitaxel was selected as a combination partner for gemcitabine because it has been shown to synergize with gemcitabine and was associated with increased intratumoral delivery of gemcitabine and stromal depletion.33 In a Phase I/II trial, the MTD of nab-paclitaxel in combination with 1,000 mg/m2 gemcitabine was established at 125 mg/m2; both agents were given weekly for the first 3 of 4 weeks (qw 3/4) in patients with advanced pancreatic cancer.33,34 For patients treated at the MTD (n=44), the ORR was 48% and median OS was 12.2 months. This led to a large multinational Phase III trial of more than 850 patients in who 125 mg/m2 nab-paclitaxel plus 1,000 mg/m2 gemcitabine qw 3/4 was compared with 1,000 mg/m2 gemcitabine alone (given weekly for 7 of 8 weeks during cycle 1 and then qw 3/4 for cycle 2 and beyond) (Table 1).35 Median OS (primary endpoint) was significantly longer with nab-paclitaxel plus gemcitabine versus gemcitabine alone (8.5 vs 6.7 months; P&lt;0.001). </plain></SENT>
<SENT sid="31468" pm="."><plain>The treatment benefit of nab-paclitaxel plus gemcitabine over gemcitabine alone was consistent across most prespecified subgroups, including those patients with more advanced disease (eg, poorer performance status, liver metastasis, ≥3 sites of metastatic disease, and carbohydrate antigen 19-9 levels 59× the upper limit of normal).35 Grade ≥3 neutropenia (38% vs 27%), fatigue (17% vs 7%), and neuropathy (17% vs 1%) were higher with nab-paclitaxel plus gemcitabine versus gemcitabine alone; no patients experienced grade 4 neuropathy in either arm. As observed in other trials,15,16,36 the grade 3 neuropathy associated with nab-paclitaxel resolved for a majority of patients and improved to grade 1 or lower in a median of 29 days. <p><text><SENT sid="31470" pm="."><plain>Nab-paclitaxel plus gemcitabine was the first gemcitabine doublet to demonstrate a clinically meaningful benefit over gemcitabine alone in a Phase III trial of advanced/metastatic pancreatic cancer.25,27–32 In 2013, nab-paclitaxel plus gemcitabine became an FDA-approved regimen for the first-line treatment of patients with metastatic pancreatic cancer.3 <p><text><SENT sid="31471" pm="."><plain>Based on the hypothesis of secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, playing a role in the delivery of nab-paclitaxel to tumors, analyses have been performed to examine the relationship between SPARC expression and outcome in patients treated with nab-paclitaxel plus gemcitabine. In the Phase I/II trial, high versus low stromal SPARC expression was associated with longer OS in the nab-paclitaxel plus gemcitabine arm (17.8 vs 8.1 months; P=0.0431), suggesting that SPARC may be a biomarker for pancreatic cancer that facilitates accumulation of nab-paclitaxel into tumors.33 An analysis of SPARC status in the Phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial found that stromal, tumor, and plasma SPARC were not prognostic for survival or predictive of survival in either treatment arm.37 </sec></sec><SecTag type="DISCUSS,CONCL"><sec><title><text><SENT sid="31473" pm="."><plain>Clinical perspectives and future directions </plain></SENT>
</text></title><sec><title><text><SENT sid="31474" pm="."><plain>Breast cancer </plain></SENT>
</text></title><p><text><SENT sid="31475" pm="."><plain>Since its approval in 2005, nab-paclitaxel has been studied in a variety of breast cancer patient populations and with varying doses and schedules.36,38 It has demonstrated efficacy in patients with poor prognostic factors and aggressive disease features,39 including those with triple-negative breast cancer (TNBC).40,41 Although the approved dose of nab-paclitaxel for the treatment of MBC is 260 mg/m2 q3w, determining the optimal dose and schedule when it is used as a single agent or in combination with other agents is an ongoing effort and a source of widely varying trial outcomes. In a preliminary analysis of the Cancer and Leukemia Group B (CALGB 40502) Phase III trial, which evaluated three combination regimens for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative MBC (nab-paclitaxel 150 mg/m2 qw 3/4 plus bevacizumab 10 mg/kg every 2 weeks [q2w] or sb-paclitaxel 90 mg/m2 qw 3/4 plus bevacizumab 10 mg/kg q2w or ixabepilone 16 mg/kg qw 3/4 plus bevacizumab 10 mg/kg q2w), similar PFS (primary endpoint) was found for the nab-paclitaxel and sb-paclitaxel arms (9.2 vs 10.6 months; HR 1.19; 95% confidence interval, 0.96–1.49; P=0.12).42 However, high rates of hematologic and non-hematologic toxicity, including peripheral neuropathy, in the nab-paclitaxel plus bevacizumab arm suggest that the 150 mg/m2 weekly schedule of nab-paclitaxel in combination with bevacizumab may not have been optimal. Early discontinuations and dose reductions due to these toxicities in the nab-paclitaxel arm may have led to insufficient dose intensity and duration of therapy. With bevacizumab’s approval being revoked by the FDA in MBC, the more pertinent clinical question is whether weekly nab-paclitaxel is superior to weekly paclitaxel in the absence of bevacizumab. A head-to-head clinical trial would help to answer this question. <p><text><SENT sid="31480" pm="."><plain>A recent large Phase III trial of 1,204 patients did demonstrate superiority of 150 mg/m2 nab-paclitaxel given weekly (n=606) over 80 mg/m2 sb-paclitaxel given weekly (n=598), both followed by epirubicin and cyclophosphamide, as neoadjuvant chemotherapy in patients with early breast cancer; pathological complete response (pCR) rates were 38% and 29%, respectively (odds ratio 1.53; P=0.001).43 Patients with TNBC appeared to derive the greatest benefit from nab-paclitaxel therapy (odds ratio 2.69; P&lt;0.001). </plain></SENT>
<SENT sid="31481" pm="."><plain>The incidence of grade ≥3 neutropenia was high with both treatments, 61% and 62%, respectively (P=0.636), whereas the incidence of grade ≥3 peripheral neuropathy was significantly higher with nab-paclitaxel (10%) versus sb-paclitaxel treatment (3%; P&lt;0.001). </plain></SENT>
<SENT sid="31482" pm="."><plain>Of note, after 400 patients were treated in the nab-paclitaxel arm, the dose of nab-paclitaxel was reduced to 125 mg/m2. </plain></SENT>
<SENT sid="31483" pm="."><plain>Long-term follow-up of this trial will determine if the increased pCR rates translate into improved disease-free survival and OS. <p><text><SENT sid="31484" pm="."><plain>A Phase II trial of 302 patients with MBC treated in the first-line demonstrated that nab-paclitaxel dosed at 150 mg/m2 qw 3/4 had a better efficacy and safety profile compared with another sb taxane, docetaxel, given at 100 mg/m2 q3w.38 The 150 mg/m2 weekly dose showed significant improvement in PFS compared with docetaxel (median 12.9 vs 7.5 months; P=0.0065) and demonstrated the longest median OS (33.8 months) compared with the other nab-paclitaxel regimens (22.2 months for 100 mg/m2 weekly and 27.7 months for 300 mg/m2 q3w) and docetaxel (26.6 months).36,38 The 150 mg/m2 dose was associated with more dose reductions and a higher incidence of grade 3 neuropathy than docetaxel (22% vs 12%); however, sensory neuropathy associated with nab-paclitaxel improved from grade 3 to grade 2 or lower in half the amount of time versus that associated with docetaxel (a median of 20 vs 41 days). <p><text><SENT sid="31485" pm="."><plain>While these clinical trial results are interesting, it is not entirely clear how relevant these doses/schedules are to clinical use. According to a recent US claims study analyzing 664 eligible records of patients with MBC, a weekly schedule of nab-paclitaxel was dispensed more often than the q3w schedule (71% vs 29%) from January 2005 to September 2012.44 Thus, it appears that the weekly dose of nab-paclitaxel has been widely adapted into clinical practice for the treatment of MBC. The recommended doses and schedules of single-agent nab-paclitaxel by the National Comprehensive Cancer Network (NCCN) for the systemic treatment of recurrent or MBC are 260 mg/m2 q3w and 100 or 150 mg/m2 qw 3/4.45 Currently, the NCCN does not recommend a nab- paclitaxel-based combination regimen for the treatment of any type of breast cancer. <p><text><SENT sid="31488" pm="."><plain>Very few treatment options exist for patients with TNBC, an aggressive disease that accounts for about 20% to 25% of all breast cancer.46 Patients with metastatic TNBC tend to be resistant to single-agent chemotherapy and often require combination chemotherapy.45 Independent trials have demonstrated activity of nab-paclitaxel in combination with carboplatin, gemcitabine, or bevacizumab for the treatment of metastatic TNBC.41,42,47 The Phase II/III Triple-Negative Albumin-Bound Paclitaxel Combination International Treatment Study (tnAcity; NCT01881230) will evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine (or carboplatin) versus gemcitabine plus carboplatin as first-line treatment of patients with TNBC (Table 2).48 During the Phase II portion of the trial, the best combination partner for nab-paclitaxel will be determined (gemcitabine or carboplatin) and carried forward into the Phase III trial where the selected nab-paclitaxel regimen will be compared with gemcitabine plus carboplatin. Planned enrollment for this trial is 790 patients and the primary endpoint is PFS. There are a number of other ongoing Phase III/IV trials evaluating the safety and efficacy of nab-paclitaxel in various breast cancer settings, and these are listed in Table 2.49–54 </sec><sec><title><text><SENT sid="31491" pm="."><plain>NSCLC </plain></SENT>
</text></title><p><text><SENT sid="31492" pm="."><plain>In the USA, &gt;70% of patients with lung cancer are 65 years of age or older and the median age of diagnosis is 70 years.55 Historically, elderly patients have been underrepresented in Phase III trials of advanced NSCLC (15% to 28% of enrolled patients were ≥70 years of age),23,56–60 thus application of these trial results to the elderly population has limitations. Other challenges in treating elderly patients include comorbidities and altered PK of drugs with age.61,62 As a result, patients above age 70 years with lung cancer tend to be undertreated due to lack of sufficient evidence. In a subset analysis of the Phase III NSCLC trial, it was found that elderly patients who were treated with nab-paclitaxel plus carboplatin had a nearly 10-month improvement in OS compared with patients treated with sb-paclitaxel plus carboplatin (P=0.009).16 The safety profile of nab-paclitaxel plus carboplatin in the elderly population was similar to the overall trial population.23 Based on this positive result, one of the Albumin-Bound Paclitaxel in NSCLC (ABOUND) Phase III trials, ABOUND.70+ (NCT02151149), will evaluate the efficacy and safety of nab-paclitaxel plus carboplatin in elderly patients (aged ≥70 years) with advanced NSCLC (Table 2).63 Patients will be randomly assigned to either 100 mg/m2 weekly nab-paclitaxel given on day 1, 8, and 15 plus carboplatin AUC 6 given on day 1 every 21 days or the same regimen with 1 week off for a 28-day cycle. Planned enrollment is 284 patients. The primary endpoint is safety (incidence of peripheral neuropathy or myelosuppression). <p><text><SENT sid="31497" pm="."><plain>Squamous NSCLC portends a poorer prognosis compared with other non-squamous subtypes, with 1- and 5-year survival rates of 14.6% and 1.6%, respectively.64 Treatment options for patients with squamous NSCLC are also limited.65 Pemetrexed and bevacizumab are not indicated for these patients, and the known mutations targetable by currently approved agents are rare in squamous NSCLC.65 Current NCCN guidelines recommend platinum-based doublets as a category 1 option, and cisplatin plus vinorelbine in combination with cetuximab as a category 2B recommendation in patients with squamous NSCLC.65 In the Phase III NSCLC trial of nab-paclitaxel plus carboplatin versus sb-paclitaxel plus carboplatin, patients with squamous histology treated with nab-paclitaxel plus carboplatin achieved an ORR that was nearly double that of patients treated with sb-paclitaxel plus carboplatin (P&lt;0.001).16 The safety profile of nab-paclitaxel plus carboplatin in patients with squamous histology was similar to the overall treated population of patients.16 This intriguing outcome provided the rationale for the Phase III ABOUND squamous maintenance trial (ABOUND.sqm; NCT02027428) that will evaluate the safety and efficacy of nab-paclitaxel as maintenance therapy after first-line treatment with nab-paclitaxel plus carboplatin in patients with stage IIIB/IV squamous-cell NSCLC (Table 2).66 After induction, patients will receive maintenance therapy of either nab-paclitaxel plus best supportive care or best supportive care alone. Planned enrollment is 260 patients and the primary endpoint is PFS. </sec><sec><title><text><SENT sid="31499" pm="."><plain>Pancreatic cancer </plain></SENT>
</text></title><p><text><SENT sid="31500" pm="."><plain>There are limited options for adjuvant therapy for pancreatic cancer and no adjuvant regimen has received regulatory approval in the USA. The NCCN guidelines recommend 5-fluorouracil (5-FU) plus leucovorin or gemcitabine as adjuvant chemotherapy options, but for chemotherapy alone, gemcitabine is preferred over 5-FU/leucovorin based on its more favorable safety profile.67 Because a majority of patients receiving adjuvant gemcitabine relapse with recurrence rates in the range of 77% to 81% in Phase III trials, better treatment options are needed.68,69 The regimen used in the Phase III MPACT trial of nab-paclitaxel plus gemcitabine versus gemcitabine is now being evaluated in the Phase III Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT; NCT01964430) as adjuvant therapy for patients with resected pancreatic cancer (Table 2).70 Patients will be randomly assigned to receive 125 mg/m2 nab-paclitaxel plus gemcitabine 1,000 mg/m2 given on days 1, 8, and 15 of a 28-day cycle for a total of six cycles or gemcitabine alone. Planned enrollment is 800 patients and the primary endpoint is disease-free survival. <p><text><SENT sid="31503" pm="."><plain>Based on the positive results of the Phase III MPACT study, there has been a significant increase in the use of nab-paclitaxel plus gemcitabine as a backbone regimen, and several studies are evaluating this combination with other novel therapies, including immunotherapy as in the Phase III Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR) trial (Table 2).71 As we move forward with this backbone regimen, future studies will likely address whether the qw 3/4 schedule, currently the FDA-approved schedule for MPC,3 will be optimal for regimens of nab-paclitaxel as a combination partner or as part of a novel sequence of regimens. </sec><sec><title><text><SENT sid="31504" pm="."><plain>Clinical benefit of nab-paclitaxel in other solid tumors </plain></SENT>
</text></title><p><text><SENT sid="31505" pm="."><plain>While nab-paclitaxel is currently only indicated by the FDA in three solid tumors, it is routinely used in the USA for the treatment of other solid tumors based on recommendations from the NCCN. At this time, melanoma and ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) are the only solid tumors outside of the current indications in which nab-paclitaxel is an NCCN-recommended treatment option.72,73 According to the NCCN guidelines, nab-paclitaxel is listed as a category 2A recommendation for the treatment of advanced or metastatic melanoma, based on positive Phase II trial data in which nab-paclitaxel led to response rates of 22% to 26% in chemotherapy-naïve patients with metastatic melanoma.74,75 Response rates have historically been &lt;20% with commonly used cytotoxics including dacarbazine, temozolomide, and sb-paclitaxel with or without carboplatin.72 In a head-to-head Phase III trial of nab-paclitaxel 150 mg/m2 qw 3/4 vs dacarbazine 1,000 mg/m2 q3w for the treatment of chemotherapy-naïve patients, nab-paclitaxel led to a significant improvement in the primary endpoint of PFS (4.8 vs 2.5 months; HR 0.792; P=0.044) and a 2-month, nonsignificant improvement in OS (12.6 vs 10.5 months; HR 0.897; P=0.271).76 Neuropathy was a common grade ≥3 treatment-related event observed with nab-paclitaxel (25% vs 0% for dacarbazine); however, these events improved by ≥1 grade in a median of 28 days. Given the advent and success of immunomodulatory drugs in the treatment of melanoma, a number of Phase II trials evaluating combinations of nab-paclitaxel with this class of drugs are underway in metastatic melanoma.77,78 <p><text><SENT sid="31508" pm="."><plain>Nab-paclitaxel also has a category 2A recommendation for the treatment of recurrent ovarian cancer.73 The NCCN recommendation for retreatment of ovarian cancer with nab-paclitaxel is based on a Phase II trial that showed an ORR of 64% and median PFS of 8.5 months.79 Patients received nab-paclitaxel dosed at 260 mg/m2 q3w. Neutropenia (24%) and neuropathy (9%; no grade 4) were the most common grade ≥3 events. In patients with platinum-sensitive recurrent ovarian cancer, platinum-based therapy either as a single agent or in combination is widely accepted as first-line therapy.73 Although nab-paclitaxel has shown activity in this setting, it has not been studied in a Phase III trial of platinum-sensitive recurrent ovarian cancer to date. Unfortunately, almost all patients with platinum-sensitive ovarian cancer will develop resistance to platinum over time.80 Platinum-resistant ovarian cancer is generally treated with non-platinum-based chemotherapy; however response rates are low and prognosis is poor. At least two Phase II trials examined the safety and efficacy of nab-paclitaxel in this setting. In a Gynecologic Oncology Group study, 47 patients with both platinum-resistant and taxane-resistant ovarian cancer were treated with nab-paclitaxel, 100 mg/m2 days 1, 8, and 15 on a 28-day schedule.81 The response rate was 23%, and 36% of patients had stable disease. A second study investigated the combination of nab-paclitaxel (using the same dosing schedule) plus bevacizumab (10 mg/kg given on days 1 and 15) in platinum-resistant patients.82 Of 48 patients enrolled, the ORR was 50% and 29% had stable disease. Taken together, these Phase II studies indicate potential activity of nab-paclitaxel against platinum-resistant ovarian cancer. Further studies are needed in this population of patients with very limited options. </sec></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="31517" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="31518" pm="."><plain>Given the success of nab-paclitaxel in the treatment of MBC, advanced or metastatic NSCLC, and metastatic pancreatic cancer, the potential for nab-paclitaxel to improve disease outcomes in settings with an unmet need should be evaluated. Several Phase III/IV studies in select populations of patients with breast cancer, NSCLC, and pancreatic cancer are currently under investigation and may lead to expanded indications of nab-paclitaxel in these disease areas (Table 2). </plain></SENT>
<SENT sid="31520" pm="."><plain>In addition, a number of Phase II trials in other solid tumors, including urothelial,81 squamous-cell carcinoma of the head and neck,83 gastric cancer,84 and colorectal and small bowel carcinoma,85 are ongoing and should provide us with information regarding the role of nab-paclitaxel in the treatment of these tumor types as well. Other encapsulated (ie, liposomes and polymers) forms of paclitaxel are in development.86 However, nab-paclitaxel is currently the only FDA- and European Medicines Agency-approved encapsulated form of paclitaxel.3,87 Differences in efficacy, safety, and PK/PD properties between these paclitaxel formulations remain to be determined in clinical trials. </sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="31522" pm="."><plain>Medical writing assistance was provided by Kerry R Garza, PhD, MediTech Media, Ltd, funded by Celgene. </p></ack></SecTag><fn-group><fn><p><text><SENT sid="31523" pm="."><plain>Disclosure <p><text><SENT sid="31524" pm="."><plain>MNK has received consulting fees for advisory board participation and for lectures from Celgene. JN has received consulting fees or honoraria for advisory board participation from Celgene. </fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="b1-dddt-9-3767"><text><SENT sid="31526" pm="."><plain>1Taxotere® (docetaxel) injection concentrate, intravenous infusion (IV) [package insert]Bridgewater, NJSanofi-Aventis2013 </plain></SENT>
</text></ref><ref id="b2-dddt-9-3767"><text><SENT sid="31527" pm="."><plain>2Taxol® (paclitaxel) injection [package insert]Princeton, NJBristol-Myers Squibb2011 </plain></SENT>
</text></ref><ref id="b3-dddt-9-3767"><text><SENT sid="31528" pm="."><plain>3Abraxane® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)Summit, NJCelgene Corporation2014 </plain></SENT>
</text></ref><ref id="b4-dddt-9-3767"><text><SENT sid="31529" pm="."><plain>4GelderblomHVerweijJNooterKSparreboomACremophor EL: the drawbacks and advantages of vehicle selection for drug formulationEur J Cancer200137131590159811527683 </plain></SENT>
</text></ref><ref id="b5-dddt-9-3767"><text><SENT sid="31530" pm="."><plain>5WeissRBDonehowerRCWiernikPHHypersensitivity reactions from taxolJ Clin Oncol199087126312681972736 </plain></SENT>
</text></ref><ref id="b6-dddt-9-3767"><text><SENT sid="31531" pm="."><plain>6ten TijeAJVerweijJLoosWJSparreboomAPharmacological effects of formulation vehicles: implications for cancer chemotherapyClin Pharmacokinet200342766568512844327 </plain></SENT>
</text></ref><ref id="b7-dddt-9-3767"><text><SENT sid="31532" pm="."><plain>7van TellingenOHuizingMTPandayVRSchellensJHNooijenWJBeijnenJHCremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patientsBr J Cancer199981233033510496361 </plain></SENT>
</text></ref><ref id="b8-dddt-9-3767"><text><SENT sid="31533" pm="."><plain>8SparreboomAvan ZuylenLBrouwerECremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsCancer Res19995971454145710197613 </plain></SENT>
</text></ref><ref id="b9-dddt-9-3767"><text><SENT sid="31534" pm="."><plain>9DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089 </plain></SENT>
</text></ref><ref id="b10-dddt-9-3767"><text><SENT sid="31535" pm="."><plain>10DesaiNTrieuVDamascelliBSoon-ShiongPSPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer PatientsTransl Oncol200922596419412420 </plain></SENT>
</text></ref><ref id="b11-dddt-9-3767"><text><SENT sid="31536" pm="."><plain>11MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287 </plain></SENT>
</text></ref><ref id="b12-dddt-9-3767"><text><SENT sid="31537" pm="."><plain>12YardleyDAnab-Paclitaxel mechanisms of action and deliveryJ Control Release2013170336537223770008 </plain></SENT>
</text></ref><ref id="b13-dddt-9-3767"><text><SENT sid="31538" pm="."><plain>13ChenNLiYYeYPalmisanoMChopraRZhouSPharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxelJ Clin Pharmacol201454101097110724719309 </plain></SENT>
</text></ref><ref id="b14-dddt-9-3767"><text><SENT sid="31539" pm="."><plain>14LiYChenNPalmisanoMZhouSPharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulationsMol Pharm20151241308131725714793 </plain></SENT>
</text></ref><ref id="b15-dddt-9-3767"><text><SENT sid="31540" pm="."><plain>15GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456 </plain></SENT>
</text></ref><ref id="b16-dddt-9-3767"><text><SENT sid="31541" pm="."><plain>16SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol201230172055206222547591 </plain></SENT>
</text></ref><ref id="b17-dddt-9-3767"><text><SENT sid="31542" pm="."><plain>17HirshVOkamotoIHonJKPatient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancerJ Thorac Oncol201491839024346096 </plain></SENT>
</text></ref><ref id="b18-dddt-9-3767"><text><SENT sid="31543" pm="."><plain>18IbrahimNKDesaiNLeghaSPhase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelClin Cancer Res2002851038104412006516 </plain></SENT>
</text></ref><ref id="b19-dddt-9-3767"><text><SENT sid="31544" pm="."><plain>19NabholtzJMGelmonKBontenbalMMulticenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ Clin Oncol1996146185818678656254 </plain></SENT>
</text></ref><ref id="b20-dddt-9-3767"><text><SENT sid="31545" pm="."><plain>20NymanDWCampbellKJHershEPhase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesJ Clin Oncol200523317785779316258082 </plain></SENT>
</text></ref><ref id="b21-dddt-9-3767"><text><SENT sid="31546" pm="."><plain>21IbrahimNKSamuelsBPageRMulticenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerJ Clin Oncol200523256019602616135470 </plain></SENT>
</text></ref><ref id="b22-dddt-9-3767"><text><SENT sid="31547" pm="."><plain>22SocinskiMAManikhasGMStroyakovskyDLA dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancerJ Thorac Oncol20105685286120521351 </plain></SENT>
</text></ref><ref id="b23-dddt-9-3767"><text><SENT sid="31548" pm="."><plain>23SocinskiMALangerCJOkamotoISafety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerAnn Oncol201324231432123123509 </plain></SENT>
</text></ref><ref id="b24-dddt-9-3767"><text><SENT sid="31549" pm="."><plain>24SocinskiMAOkamotoIHonJKSafety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancerAnn Oncol20132492390239623842283 </plain></SENT>
</text></ref><ref id="b25-dddt-9-3767"><text><SENT sid="31550" pm="."><plain>25BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156 </plain></SENT>
</text></ref><ref id="b26-dddt-9-3767"><text><SENT sid="31551" pm="."><plain>26Tarceva® (erlotinib) tablets, for oral use [package insert]South San Francisco, CAGenentech USA, Inc2014 </plain></SENT>
</text></ref><ref id="b27-dddt-9-3767"><text><SENT sid="31552" pm="."><plain>27MooreMJGoldsteinDHammJNational Cancer Institute of Canada Clinical Trials GroupErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677 </plain></SENT>
</text></ref><ref id="b28-dddt-9-3767"><text><SENT sid="31553" pm="."><plain>28BerlinJDCatalanoPThomasJPKuglerJWHallerDGBensonAB3rdPhase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297J Clin Oncol200220153270327512149301 </plain></SENT>
</text></ref><ref id="b29-dddt-9-3767"><text><SENT sid="31554" pm="."><plain>29Abou-AlfaGKLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol200624274441444716983112 </plain></SENT>
</text></ref><ref id="b30-dddt-9-3767"><text><SENT sid="31555" pm="."><plain>30HerrmannRBodokyGRuhstallerTSwiss Group for Clinical Cancer Research; Central European Cooperative Oncology GroupGemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJ Clin Oncol200725162212221717538165 </plain></SENT>
</text></ref><ref id="b31-dddt-9-3767"><text><SENT sid="31556" pm="."><plain>31LouvetCLabiancaRHammelPGERCOR; GISCADGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol200523153509351615908661 </plain></SENT>
</text></ref><ref id="b32-dddt-9-3767"><text><SENT sid="31557" pm="."><plain>32Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol200422183776378315365074 </plain></SENT>
</text></ref><ref id="b33-dddt-9-3767"><text><SENT sid="31558" pm="."><plain>33Von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol201129344548455421969517 </plain></SENT>
</text></ref><ref id="b34-dddt-9-3767"><text><SENT sid="31559" pm="."><plain>34FreseKKNeesseACookNnab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancerCancer Discov20122326026922585996 </plain></SENT>
</text></ref><ref id="b35-dddt-9-3767"><text><SENT sid="31560" pm="."><plain>35Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140 </plain></SENT>
</text></ref><ref id="b36-dddt-9-3767"><text><SENT sid="31561" pm="."><plain>36GradisharWJKrasnojonDCheporovSPhase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survivalClin Breast Cancer201212531332122728026 </plain></SENT>
</text></ref><ref id="b37-dddt-9-3767"><text><SENT sid="31562" pm="."><plain>37HidalgoMPlazaCIlleiPBSPARC analysis in the phase III MPACT trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancerAnn Oncol201525Suppl 2ii106 </plain></SENT>
</text></ref><ref id="b38-dddt-9-3767"><text><SENT sid="31563" pm="."><plain>38GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941 </plain></SENT>
</text></ref><ref id="b39-dddt-9-3767"><text><SENT sid="31564" pm="."><plain>39O’ShaughnessyJGradisharWJBharPIglesiasJNab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysisBreast Cancer Res Treat2013138382983723563958 </plain></SENT>
</text></ref><ref id="b40-dddt-9-3767"><text><SENT sid="31565" pm="."><plain>40LoboCLopesGBaezOFinal results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerBreast Cancer Res Treat2010123242743520585851 </plain></SENT>
</text></ref><ref id="b41-dddt-9-3767"><text><SENT sid="31566" pm="."><plain>41HamiltonEKimmickGHopkinsJNab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancerClin Breast Cancer201313641642024099649 </plain></SENT>
</text></ref><ref id="b42-dddt-9-3767"><text><SENT sid="31567" pm="."><plain>42RugoHSBarryWTMoreno-AspitiaACALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone +/− bevacizumab as first-line therapy for locally recurrent or metastatic breast cancerJ Clin Oncol201230SupplAbstract CRA1002 </plain></SENT>
</text></ref><ref id="b43-dddt-9-3767"><text><SENT sid="31568" pm="."><plain>43UntchMJackischCSchneeweissAA randomized phase III trial comparing nanoparticle-based (nab) paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer GBG 69 (GeparSepto)Abstract S2-07Presented at: 2014 San Antonio Breast Cancer SymposiumDecember 9–13 2014San Antonio, TexasAvailable from: <ext-link ext-link-type="uri" xlink:href="http://www.sabcs.org/">http://www.sabcs.org/</ext-link>Accessed May 7, 2015 </plain></SENT>
</text></ref><ref id="b44-dddt-9-3767"><text><SENT sid="31569" pm="."><plain>44PattDLiangCLiLSafety and efficacy of nab-paclitaxel in patients with metastatic breast cancer: real-world results from a US health insurance databaseJ Clin Oncol20145sSupplAbstract 1075. </plain></SENT>
<SENT sid="31570" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://sabcs.org/programschedule/PosterSessions.asp?SessionGroupID=154">http://sabcs.org/programschedule/PosterSessions.asp?SessionGroupID=154</ext-link>Accessed July 9, 2015 </plain></SENT>
</text></ref><ref id="b45-dddt-9-3767"><text><SENT sid="31571" pm="."><plain>45NCCN Clinical Practice Guidelines in OncologyBreast Cancer V22015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf">http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</ext-link>Accessed March 16, 2015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf">http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</ext-link>Accessed July 9, 2015 </plain></SENT>
</text></ref><ref id="b46-dddt-9-3767"><text><SENT sid="31572" pm="."><plain>46LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128118250347 </plain></SENT>
</text></ref><ref id="b47-dddt-9-3767"><text><SENT sid="31573" pm="."><plain>47RoyVLaPlantBRGrossGGBaneCLPalmieriFMNorth Central Cancer Treatment GroupPhase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Ann Oncol200920344945319087987 </plain></SENT>
</text></ref><ref id="b48-dddt-9-3767"><text><SENT sid="31574" pm="."><plain>48Celgene CorporationEvaluate risk/benefit of nab paclitaxel in combination with gemcitabine and carboplatin compared to gemcitabine and carboplatin in triple negative metastatic breast cancer (or metastatic triple negative breast cancer) (tnAcity)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated June 12, 2015]. </plain></SENT>
<SENT sid="31575" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT01881230">https://clinicaltrials.gov/show/NCT01881230</ext-link>. </plain></SENT>
<SENT sid="31576" pm="."><plain>NLM identifier: NCT01881230Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b49-dddt-9-3767"><text><SENT sid="31577" pm="."><plain>49HofmannDNitzUGluzOWSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trialTrials20131426123958221 </plain></SENT>
</text></ref><ref id="b50-dddt-9-3767"><text><SENT sid="31578" pm="."><plain>50West German Study GroupAdjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated May 18, 2015]. </plain></SENT>
<SENT sid="31579" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01781338">https://clinicaltrials.gov/ct2/show/NCT01781338</ext-link>. </plain></SENT>
<SENT sid="31580" pm="."><plain>NLM identifier: NCT01781338Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b51-dddt-9-3767"><text><SENT sid="31581" pm="."><plain>51Fondazione MichelangeloNeoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer (ETNA)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated May 25, 2015]. </plain></SENT>
<SENT sid="31582" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01822314">https://clinicaltrials.gov/ct2/show/NCT01822314</ext-link>. </plain></SENT>
<SENT sid="31583" pm="."><plain>NLM identifier: NCT01822314Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b52-dddt-9-3767"><text><SENT sid="31584" pm="."><plain>52German Breast GroupStudy of nab-paclitaxel in high risk early breast cancer (GAIN-2)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2012[updated November 26, 2015]. </plain></SENT>
<SENT sid="31585" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01690702">https://clinicaltrials.gov/ct2/show/NCT01690702</ext-link>. </plain></SENT>
<SENT sid="31586" pm="."><plain>NLM identifier: NCT01690702Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b53-dddt-9-3767"><text><SENT sid="31587" pm="."><plain>53Hoffmann-La RocheA study of Perjeta (pertuzumab) and Herceptin (trastuzumab) treatment in combination with a taxane in patients with advanced HER2-positive breast cancerClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated June 1, 2015]. </plain></SENT>
<SENT sid="31588" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02019277">https://clinicaltrials.gov/ct2/show/NCT02019277</ext-link>. </plain></SENT>
<SENT sid="31589" pm="."><plain>NLM identifier: NCT02019277Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b54-dddt-9-3767"><text><SENT sid="31590" pm="."><plain>54Hoffmann-La RocheA study of pertuzumab in combination with Herceptin (trastuzumab) and a taxane in first-line treatment in patients with HER2-positive advanced breast cancer (PERUSE)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2012[updated June 1, 2015]. </plain></SENT>
<SENT sid="31591" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01572038">https://clinicaltrials.gov/ct2/show/NCT01572038</ext-link>. </plain></SENT>
<SENT sid="31592" pm="."><plain>NLM identifier: NCT01572038Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b55-dddt-9-3767"><text><SENT sid="31593" pm="."><plain>55HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2010 [web page on the Internet]Bethesda, MDNational Cancer Institute2013[updated June 14, 2013]. </plain></SENT>
<SENT sid="31594" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/archive/csr/1975_2010/">http://seer.cancer.gov/archive/csr/1975_2010/</ext-link>Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b56-dddt-9-3767"><text><SENT sid="31595" pm="."><plain>56LangerCJManolaJBernardoPCisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trialJ Natl Cancer Inst200294317318111830607 </plain></SENT>
</text></ref><ref id="b57-dddt-9-3767"><text><SENT sid="31596" pm="."><plain>57LangerCJVangelMSchillerJAge-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (&lt;70)Proc Am Soc Clin Oncol200322639 </plain></SENT>
</text></ref><ref id="b58-dddt-9-3767"><text><SENT sid="31597" pm="."><plain>58LilenbaumRCHerndonJEIIListMASingle-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)J Clin Oncol200523119019615625373 </plain></SENT>
</text></ref><ref id="b59-dddt-9-3767"><text><SENT sid="31598" pm="."><plain>59BlanchardEMMoonJHeskethPJComparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509J Thorac Oncol20116111512021107287 </plain></SENT>
</text></ref><ref id="b60-dddt-9-3767"><text><SENT sid="31599" pm="."><plain>60RamalingamSSDahlbergSELangerCJEastern Cooperative Oncology GroupOutcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599J Clin Oncol2008261606518165641 </plain></SENT>
</text></ref><ref id="b61-dddt-9-3767"><text><SENT sid="31600" pm="."><plain>61SehlMSawhneyRNaeimAPhysiologic aspects of aging: impact on cancer management and decision making, part IICancer J200511646147316393480 </plain></SENT>
</text></ref><ref id="b62-dddt-9-3767"><text><SENT sid="31601" pm="."><plain>62AymannsCKellerFMausSHartmannBCzockDReview on pharmacokinetics and pharmacodynamics and the aging kidneyClin J Am Soc Nephrol20105231432720056753 </plain></SENT>
</text></ref><ref id="b63-dddt-9-3767"><text><SENT sid="31602" pm="."><plain>63Celgene CorporationSafety and efficacy study of Abraxane in combination with carboplatin to treat advanced NSCL cancer in the elderly (ABOUND 70+)Available from: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02151149">https://www.clinicaltrials.gov/ct2/show/NCT02151149</ext-link>. </plain></SENT>
<SENT sid="31603" pm="."><plain>NLM identifier: NCT02151149Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b64-dddt-9-3767"><text><SENT sid="31604" pm="."><plain>64CetinKEttingerDSHeiYJO’MalleyCDSurvival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results ProgramClin Epidemiol2011313914821607015 </plain></SENT>
</text></ref><ref id="b65-dddt-9-3767"><text><SENT sid="31605" pm="."><plain>65NCCN Clinical Practice Guidelines in OncologyNon-Small Cell Lung Cancer. V52015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link>Accessed March 16, 2015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link>Accessed July 9, 2015 </plain></SENT>
</text></ref><ref id="b66-dddt-9-3767"><text><SENT sid="31607" pm="."><plain>66Celgene CorporationSafety and efficacy study of Abraxane as maintenance treatment after Abraxane plus carboplatin in 1st line stage IIIB/IV squamous cell non-small cell lung cancer (aboundsqm)Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02027428">https://clinicaltrials.gov/ct2/show/NCT02027428</ext-link>. </plain></SENT>
<SENT sid="31608" pm="."><plain>NLM identifier: NCT02027428Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b67-dddt-9-3767"><text><SENT sid="31609" pm="."><plain>67NCCN Clinical Practice Guidelines in OncologyPancreatic Adenocarcinoma. V22015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf">http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf</ext-link>Accessed March 16, 2015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf">http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf</ext-link>Accessed July 9, 2015 </plain></SENT>
</text></ref><ref id="b68-dddt-9-3767"><text><SENT sid="31611" pm="."><plain>68OettleHNeuhausPHochhausAAdjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trialJAMA2013310141473148124104372 </plain></SENT>
</text></ref><ref id="b69-dddt-9-3767"><text><SENT sid="31612" pm="."><plain>69UenoHKosugeTMatsuyamaYA randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBr J Cancer2009101690891519690548 </plain></SENT>
</text></ref><ref id="b70-dddt-9-3767"><text><SENT sid="31613" pm="."><plain>70Celgene CorporationNab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the “Apact” study) (apact)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated June 5, 2015]. </plain></SENT>
<SENT sid="31614" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01964430">https://clinicaltrials.gov/ct2/show/NCT01964430</ext-link>. </plain></SENT>
<SENT sid="31615" pm="."><plain>NLM identifier: NCT01964430Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b71-dddt-9-3767"><text><SENT sid="31616" pm="."><plain>71NewLink Genetics CorporationImmunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated March 26, 2015]. </plain></SENT>
<SENT sid="31617" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01836432">https://clinicaltrials.gov/ct2/show/NCT01836432</ext-link>. </plain></SENT>
<SENT sid="31618" pm="."><plain>NLM identifier: NCT01836432Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b72-dddt-9-3767"><text><SENT sid="31619" pm="."><plain>72NCCN Clinical Practice Guidelines in OncologyMelanoma. V22015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf">http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf</ext-link>Accessed March 16, 2015 </plain></SENT>
</text></ref><ref id="b73-dddt-9-3767"><text><SENT sid="31621" pm="."><plain>73NCCN Clinical Practice Guidelines in OncologyOvarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V12015Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf">http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</ext-link>Accessed March 16, 2015 </plain></SENT>
</text></ref><ref id="b74-dddt-9-3767"><text><SENT sid="31623" pm="."><plain>74HershEMO’DaySJRibasAA phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanomaCancer2010116115516319877111 </plain></SENT>
</text></ref><ref id="b75-dddt-9-3767"><text><SENT sid="31624" pm="."><plain>75KottschadeLASumanVJAmatrudaTIIIA phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1)Cancer201111781704171021472717 </plain></SENT>
</text></ref><ref id="b76-dddt-9-3767"><text><SENT sid="31625" pm="."><plain>76HershEDel VecchioMBrownMPFinal overall survival from a phase III trial of nab-paclitaxel vs dacarbazine in chemotherapy-naive patients with metastatic melanomaJ Clin Oncol20145sSupplAbstract 9045 </plain></SENT>
</text></ref><ref id="b77-dddt-9-3767"><text><SENT sid="31626" pm="."><plain>77Academic and Community Cancer Research UnitedPaclitaxel albumin-stabilized nanoparticle formulation and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgeryClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2014[updated June 15, 2015]. </plain></SENT>
<SENT sid="31627" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02158520">https://clinicaltrials.gov/ct2/show/NCT02158520</ext-link>. </plain></SENT>
<SENT sid="31628" pm="."><plain>NLM identifier: NCT02158520Accessed June 22, 2015 </plain></SENT>
</text></ref><ref id="b78-dddt-9-3767"><text><SENT sid="31629" pm="."><plain>78MD Anderson Cancer CenterPhase II study of Abraxane plus ipilimumab in patients with metastatic melanomaClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013[updated December 18, 2014]. </plain></SENT>
<SENT sid="31630" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01827111">https://clinicaltrials.gov/ct2/show/NCT01827111</ext-link>. </plain></SENT>
<SENT sid="31631" pm="."><plain>NLM identifier: NCT01827111Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b79-dddt-9-3767"><text><SENT sid="31632" pm="."><plain>79TenerielloMGTsengPCCrozierMPhase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancerJ Clin Oncol20092791426143119224848 </plain></SENT>
</text></ref><ref id="b80-dddt-9-3767"><text><SENT sid="31633" pm="."><plain>80LuveroDMilaniALedermannJATreatment options in recurrent ovarian cancer: latest evidence and clinical potentialTher Adv Med Oncol20146522923925342990 </plain></SENT>
</text></ref><ref id="b81-dddt-9-3767"><text><SENT sid="31634" pm="."><plain>81ColemanRLBradyWEMcMeekinDSA phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group studyGynecol Oncol2011122111111521497382 </plain></SENT>
</text></ref><ref id="b82-dddt-9-3767"><text><SENT sid="31635" pm="."><plain>82TillmannsTDLoweMPWalkerMSStepanskiEJSchwartzbergLSPhase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinomaGynecol Oncol2013128222122822960352 </plain></SENT>
</text></ref><ref id="b83-dddt-9-3767"><text><SENT sid="31636" pm="."><plain>83UNC Lineberger Comprehensive Cancer CenterInduction chemotherapy for locally advanced squamous cell carcinoma of the head and neckClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2011[updated February 28, 2014]. </plain></SENT>
<SENT sid="31637" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01412229">https://clinicaltrials.gov/ct2/show/NCT01412229</ext-link>. </plain></SENT>
<SENT sid="31638" pm="."><plain>NLM identifier: NCT01412229Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b84-dddt-9-3767"><text><SENT sid="31639" pm="."><plain>84Chinese Academy of Medical SciencesFirst line chemotherapy for advanced cancer (GC-A-003)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2013Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01980810">https://clinicaltrials.gov/ct2/show/NCT01980810</ext-link>. </plain></SENT>
<SENT sid="31640" pm="."><plain>NLM identifier: NCT01980810Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b85-dddt-9-3767"><text><SENT sid="31641" pm="."><plain>85MD Anderson Cancer CenterAbraxane in CIMP-high colorectal and small bowel adenocarcinomasClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2012[updated February 9, 2015]. </plain></SENT>
<SENT sid="31642" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01730586">https://clinicaltrials.gov/ct2/show/NCT01730586</ext-link>. </plain></SENT>
<SENT sid="31643" pm="."><plain>NLM identifier: NCT01730586Accessed May 4, 2015 </plain></SENT>
</text></ref><ref id="b86-dddt-9-3767"><text><SENT sid="31644" pm="."><plain>86MaPMumperRJPaclitaxel Nano-Delivery Systems: A Comprehensive ReviewJ Nanomed Nanotechnol201342100016424163786 </plain></SENT>
</text></ref><ref id="b87-dddt-9-3767"><text><SENT sid="31645" pm="."><plain>87Celgene Europe LimitedAbraxane [summary of product characteristics]LondonEuropean Medicines Agencynd. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf</ext-link>Accessed June 4, 2015 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="t1-dddt-9-3767" position="float"><label>Table 1</label><caption><p><text><SENT sid="31647" pm="."><plain>Phase III registration trials of albumin-bound paclitaxel (nab-P) in breast, non-small-cell lung, and pancreatic cancers </caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="31648" pm="."><plain>Phase III trial </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="31649" pm="."><plain>Patient population </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="31650" pm="."><plain>Regimen </plain></SENT>
</text></th><th colspan="3" valign="top" align="left" rowspan="1"><text><SENT sid="31651" pm="."><plain>Efficacy  </plain></SENT>
</text></th><th colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="31652" pm="."><plain>Select grade ≥3 AEs, %  </plain></SENT>
</text></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31653" pm="."><plain>ORR, % </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31654" pm="."><plain>Median PFS, mo </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31655" pm="."><plain>Median OS, mo </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31656" pm="."><plain>Neutropenia </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31657" pm="."><plain>Neuropathy </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="8" valign="top" align="left" rowspan="1"><text><SENT sid="31658" pm="."><plain>Breast cancer </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31659" pm="."><plain>Gradishar et al15 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31660" pm="."><plain>First-line (n=97) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31661" pm="."><plain>Nab-P 260 mg/m2 30-minute infusion q3w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31662" pm="."><plain>33 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31663" pm="."><plain>TTP 5.3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31664" pm="."><plain>14.9 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31665" pm="."><plain>30 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31666" pm="."><plain>10a </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31667" pm="."><plain>Second-line or later (n=132) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31668" pm="."><plain>First-line (n=89) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31669" pm="."><plain>sb-P 175 mg/m2 3-hour infusion q3w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31670" pm="."><plain>19 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31671" pm="."><plain>TTP 3.9 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31672" pm="."><plain>12.8 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31673" pm="."><plain>45 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31674" pm="."><plain>2a </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31675" pm="."><plain>Second-line or later (n=136) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31676" pm="."><plain>P=0.001 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31677" pm="."><plain>P=0.006 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31678" pm="."><plain>P=0.374 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31679" pm="."><plain>P&lt;0.05 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31680" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><text><SENT sid="31681" pm="."><plain>Non-small-cell lung cancer </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31682" pm="."><plain>Socinski et al16 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31683" pm="."><plain>First-line (n=521) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31684" pm="."><plain>Nab-P100 mg/m2 30-minute infusion on days 1, 8, and 15 followed by carbo AUC 6 mg/mL/min on day 1 q3w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31685" pm="."><plain>33 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31686" pm="."><plain>6.3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31687" pm="."><plain>12.1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31688" pm="."><plain>47 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31689" pm="."><plain>3a </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31690" pm="."><plain>First-line (n=531) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31691" pm="."><plain>sb-P 200 mg/m2 3-hour infusion + carbo AUC 6 mg/mL/min, both given q3w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31692" pm="."><plain>25 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31693" pm="."><plain>5.8 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31694" pm="."><plain>11.2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31695" pm="."><plain>58 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31696" pm="."><plain>12 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31697" pm="."><plain>P=0.005 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31698" pm="."><plain>P=0.214 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31699" pm="."><plain>P=0.271 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31700" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31701" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><text><SENT sid="31702" pm="."><plain>Pancreatic cancer </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31703" pm="."><plain>Von Hoff et al35 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31704" pm="."><plain>First-line (n=431) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31705" pm="."><plain>Nab-P 125 mg/m2 30- to 40-minute infusion followed by gem 1,000 mg/m2 on days 1, 8, and 15 every 4 weeks </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31706" pm="."><plain>23 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31707" pm="."><plain>5.5 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31708" pm="."><plain>8.5 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31709" pm="."><plain>38 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31710" pm="."><plain>17 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31711" pm="."><plain>First-line (n=430) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31712" pm="."><plain>Gem 1,000 mg/m2 weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31713" pm="."><plain>7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31714" pm="."><plain>3.7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31715" pm="."><plain>6.7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31716" pm="."><plain>27 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31717" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31718" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31719" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31720" pm="."><plain>P&lt;0.001 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn1-dddt-9-3767"><label>a</label><p>Grade 3 only.</p></fn><fn id="tfn2-dddt-9-3767"><p><bold>Abbreviations:</bold> AEs, adverse events; AUC, area under the concentration–time curve; carbo, carboplatin; gem, gemcitabine; mo, month; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; q3w, every 3 weeks; sb-P, sb-paclitaxel; TTP, time to progression.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-dddt-9-3767" position="float"><label>Table 2</label><caption><p><text><SENT sid="31721" pm="."><plain>Phase III/IV clinical trials of albumin-bound paclitaxel (nab-P) </caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31722" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31723" pm="."><plain>Trial description </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31724" pm="."><plain>Treatment </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31725" pm="."><plain>Primary endpoint </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31726" pm="."><plain>Planned enrollment </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31727" pm="."><plain>Planned primary completion </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" rowspan="1"><text><SENT sid="31728" pm="."><plain>BC </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31729" pm="."><plain>NCT0188123048 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31730" pm="."><plain>Phase II/III tnAcity trial: evaluate risk/benefit of nab-P in combination with gem and carbo compared with gem and carbo in metastatic TNBC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31731" pm="."><plain>Nab-P 125 mg/m2 + gem 1,000 mg/m2 qw 2/3 vs nab-P 125 mg/m2 + carbo AUC 2 qw 2/3 vs gem 1,000 mg/m2 + carbo AUC 2 qw 2/3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31732" pm="."><plain>PFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31733" pm="."><plain>790 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31734" pm="."><plain>October 2015 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31735" pm="."><plain>NCT0178133849,50 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31736" pm="."><plain>Phase II/III ADAPT trial: adjuvant dynamic marker- adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31737" pm="."><plain>Nab-P 125 mg/m2 qw or sb-pac 175 mg/m2 q2w; both in combination with epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 q2w for 8 weeks </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31738" pm="."><plain>Identification of a responder subpopulation within intermediate- and high-risk groups in any BC subtype, which due to therapy has a comparable outcome to a low-risk group </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31739" pm="."><plain>4,936 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31740" pm="."><plain>April 2020 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31741" pm="."><plain>NCT0182231451 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31742" pm="."><plain>Phase III ETNA trial: neoadjuvant chemotherapy with nab-P in women with HER2-negative high-risk BC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31743" pm="."><plain>Nab-p 125 mg/m2 qw 3/4×4 cycles vs sb-P 90 mg/mg2 qw 3/4×4 cycles; both followed by AC or EC or FEC q3w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31744" pm="."><plain>pCR </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31745" pm="."><plain>632 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31746" pm="."><plain>September 2016 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31747" pm="."><plain>NCT0169070252 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31748" pm="."><plain>Phase III GAIN-2 trial: study of nab-P in high-risk early BC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31749" pm="."><plain>EC + nab-Pa 260–330 mg/mg2 q2w vs EC + docetaxel </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31750" pm="."><plain>DFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31751" pm="."><plain>2,886 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31752" pm="."><plain>January 2016 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31753" pm="."><plain>NCT0201927753 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31754" pm="."><plain>Phase III trial: study of pertuzumab and trastuzumab in combination with a taxane in patients with advanced HER2-positive BC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31755" pm="."><plain>Pertuzumab, trastuzumab, and taxane (investigators’ choice of docetaxel, paclitaxel, or nab-P) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31756" pm="."><plain>Safety </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31757" pm="."><plain>50 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31758" pm="."><plain>May 2017 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31759" pm="."><plain>NCT0157203854 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31760" pm="."><plain>Phase III PERUSE trial: study of pertuzumab in combination with trastuzumab and a taxane in first-line treatment in patients with HER2-positive advanced BC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31761" pm="."><plain>Pertuzumab, trastuzumab, and taxane (investigators’ choice of docetaxel, paclitaxel, or nab-P) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31762" pm="."><plain>Safety </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31763" pm="."><plain>1,500 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31764" pm="."><plain>May 2018 </plain></SENT>
</text></td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1"><text><SENT sid="31765" pm="."><plain>NSCLC </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31766" pm="."><plain>NCT0215114963 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31767" pm="."><plain>Phase IV ABOUND.70+ trial: safety and efficacy study of nab-P in combination with carbo to treat advanced NSCLC in the elderly </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31768" pm="."><plain>Nab-P 100 mg/m2 + carbo AUC 6 q3w vs nab-P 100 mg/m2 + carbo AUC 6 q4w </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31769" pm="."><plain>Incidence of peripheral neuropathy and myelosuppression </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31770" pm="."><plain>284 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31771" pm="."><plain>December 2016 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31772" pm="."><plain>NCT0202742866 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31773" pm="."><plain>Phase III ABOUND.sqm trial: safety and efficacy study of nab-P as maintenance therapy after nab-P plus carbo in first-line stage IIIB/IV squamous-cell NSCLC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31774" pm="."><plain>Induction: nab-P 100 mg/m2 qw + carbo AUC 6 q3w ×4 cycles Maintenance: nab-P 100 mg/m2 qw 2/3 or best supportive care </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31775" pm="."><plain>PFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31776" pm="."><plain>260 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31777" pm="."><plain>May 2016 </plain></SENT>
</text></td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1"><text><SENT sid="31778" pm="."><plain>PC </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31779" pm="."><plain>NCT0196443070 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31780" pm="."><plain>Phase III APACT trial: nab-P and gem vs gem alone as adjuvant therapy for patients with resected PC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31781" pm="."><plain>Nab-P 125 mg/m2 + gem 1,000 mg/m2 qw 3/4 vs gem 1,000 mg/m2 qw 3/4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31782" pm="."><plain>DFS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31783" pm="."><plain>800 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31784" pm="."><plain>April 2019 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31785" pm="."><plain>NCT0183643271 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31786" pm="."><plain>Phase III PILLAR: immunotherapy study in borderline resectable or locally advanced unresectable PC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31787" pm="."><plain>FOLFIRINOX or nab-P 125 mg/m2 + gem 1,000 mg/m2 qw 3/4 with or without algenpantucel-L immunotherapy </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31788" pm="."><plain>OS </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31789" pm="."><plain>280 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="31790" pm="."><plain>September 2015 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn3-dddt-9-3767"><label>a</label><p><italic>Nab</italic>-P dose to be determined in a run-in phase.</p></fn><fn id="tfn4-dddt-9-3767"><p><bold>Abbreviations:</bold> ABOUND.70+, Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (70+); ABOUND.sqm, Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB/IV Squamous Cell Non-small Cell Lung Cancer (abound); AC, doxorubicin and cyclophosphamide; ADAPT, Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial; APACT, Adjuvant Pancreatic Adenocarcinoma Clinical Trial; AUC, area under the concentration-time curve; BC, breast cancer; carbo, carboplatin; DFS, disease-free survival; EC, epirubicin and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; FOLFIRINOX, leucovorin, 5-fluorouracil, irinotecan, oxaliplatin; gem, gemcitabine; HER2, human epidermal growth factor receptor 2; NSCLC, non-small-cell lung cancer; OS, overall survival; PC, pancreatic cancer; pCR, pathologic complete response; PERUSE, Phase III trial of pertuzumab in combination with trastuzumab and a taxane in first-line treatment in patients with HER2-positive advanced BC; PFS, progression-free survival; Phase PILLAR, Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer; qw 2/3, first 2 of 3 weeks; qw 3/4, first 3 of 4 weeks; qw, weekly; q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; sb-P, solvent-based paclitaxel; tnAcity, Triple-Negative Albumin-Bound Paclitaxel Combination International Treatment Study; TNBC, triple-negative breast cancer.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
